DCIK细胞联合化疗治疗晚期消化道肿瘤的临床疗效  

Clinical studies on effects of chemotherapy treatment combined with adoptive immunotherapy in patients of advanced digestive malignant tumor

作　　者：莫晨[1] 黄燕苹[1] 吴小娥[1] 陕海丽[1] 高锦[2] 王大鹏[2] 徐铭宝[1] 

机构地区：[1]武警总医院干部病房二科,北京100039 [2]中国科学院生物物理研究所,北京100101

出　　处：《现代肿瘤医学》2011年第3期479-483,共5页Journal of Modern Oncology

基　　金：内蒙古自治区社会发展领域创新引导奖励资金计划(No.20091907)

摘　　要：目的:评价树突状细胞调节的细胞因子诱导的杀伤细胞(DC activated and cytokins induced killer,DCIK)联合化疗治疗晚期消化道肿瘤的疗效。方法:实验采用武警总医院2005年6月至2007年8月应用DCIK联合全身化疗治疗晚期消化道肿瘤的患者23例作为联合治疗组。同期进行单纯化疗的20例晚期消化道肿瘤患者作为对照组。联合治疗组患者均于化疗前采集外周血单个核细胞(PBMC)。将PBMC体外培养产生DCIK细胞。联合治疗组患者首先行2周期全身化疗,化疗结束后回输质量合格的DCIK细胞。单纯化疗组仅进行2周期全身化疗。观察两组近期疗效、临床受益反应改善程度、肿瘤标志物、免疫指标及1年、3年生存率。结果:两组近期疗效无显著性差异(P>0.05)。联合治疗组治疗后KPS评分升高(P<0.05),单纯化疗组治疗后KPS评分较治疗前无改善(P>0.05)。联合治疗组患者治疗后外周血CD3+CD8+、CD3+CD56+细胞的比例大幅升高(P<0.01);而单纯化疗组患者无明显变化(P>0.05)。联合治疗组1年生存率78.3%;单纯化疗组1年生存率80%(P>0.05)。联合治疗组3年生存率52.2%;单纯化疗组3年生存率30%(P<0.01)。结论:DCIK联合化疗治疗晚期消化道肿瘤具有更好的疗效,其临床受益反应有较大的提高,免疫功能有所改善,3年生存率提高。Objective：To evaluate the clinical anti-cancer efficacy of DC activated and Cytokine induced Killer Cells（DCIK） combined with chemotherapy in treating patients of advanced digestive malignant tumor（DMT）.Methods：Twenty three patients diagnosed as advanced DMT in General Hospital of Chinese Armed Police Forces from 2005 to 2007 were treated by DCIK combined with systemic chemotherapy as combination therapy group,20 advanced DMT patients at the same time were treated by chemotherapy only as control group.Peripheral blood mononuclear cells（PBMC） were isolated from patients of combination therapy group before chemotherapy.PBMC were induced to DCIK cells in vitro.The qualified DCIK cells were administered to the patients of combination group after 2 periods of systemic chemotherapy.The patients of chemotherapy group were treated with 2 periods of systemic chemotherapy only.Short-term effect,the improvement degree of clinical benefit response,serum tumor markers,immunological indexes and 1-year,3-year survival rate were observed.Results：The short-term effect of 2 groups was of no significant difference（P 0.05）.KPS score of combination therapy group was increased（P0.05） after treatment than that of before,while KPS score of chemotherapy group showed no improvement（P0.05）after treatment.The peripheral blood CD3＋CD8＋,CD3＋ CD56＋ cells of combination therapy group were significantly increased（P0.01） after treatment than that of before,while the CD3＋CD8＋,CD3＋CD56＋ cells of chemotherapy group were no significant change（P 0.05）.1-year survival rate of combined therapy group was 78.3%;1-year survival rate of chemotherapy group was 80%（P 0.05）.3-year survival rate of combination therapy group was 52.2%;3-year survival rate of chemotherapy group was 30%（P0.01）.Conclusion：DCIK combined with chemotherapy have better clinical anti-cancer efficacy,quality of life,immune function and 3-year survival rate in treatment of advanced digestive malignant tumor.

关 键 词：树突状细胞调节的细胞因子诱导的杀伤细胞 细胞因子诱导的杀伤细胞 树突状细胞 消化道恶性肿瘤 过继性细胞免疫治疗 化疗 

分 类 号：R735[医药卫生—肿瘤]